At Ace Therapeutics, we offer comprehensive solutions for clients focused on glaucoma research, providing reliable Endothelin-1 (ET-1)-induced glaucoma models to support your study needs. Our models recapitulate human glaucoma pathophysiology with high fidelity, enabling robust evaluation of drug candidates, gene therapies, and neuroprotective interventions.
The Role of Endothelin-1 in Glaucoma Pathogenesis
ET-1 is a potent vasoconstrictor peptide that plays a significant role in glaucoma pathogenesis. Elevated ET-1 levels are associated with increased intraocular pressure (IOP) and neurodegeneration, contributing to optic nerve damage and retinal ganglion cell (RGC) loss. ET-1 acts through ETA and ETB receptors, promoting vasoconstriction, reducing ocular blood flow, and triggering neuroinflammation via glial cell activation. These mechanisms collectively drive the progression of glaucoma. Chronic ET-1 administration in animal models mimics key features of primary open-angle glaucoma (POAG), including sustained IOP elevation, axonal injury, and oligodendrocyte loss, providing a clinically relevant platform for mechanistic and therapeutic studies.
Fig. 1 Retinal vasculature fluorescein angiography and vascular density analysis in Brown Norway rats. Rats were either treated or untreated with macitentan (endothelin receptor antagonist) for three days before intravitreal injection of ET-1. (Kodati B, et al., 2023)
Explore Our ET-1-Induced Glaucoma Models
From model customization to endpoint analysis, Ace Therapeutics provides end-to-end support tailored to your research goals. Our ET-1-induced glaucoma models provide a reliable and reproducible platform for glaucoma research and drug evaluation.
Development and Optimization of ET-1-Induced Glaucoma Models
Available Models
We provide a range of ET-1-induced glaucoma models, including rodent models that are ideal for detailed study of neurodegenerative changes and optic nerve damage. Species-specific models are also available, and we tailor models to match the specific requirements of your research, ensuring relevance and applicability to human disease.
Key Features of ET-1-Induced Glaucoma Models
- Clinically relevant IOP dynamics
Sustained IOP elevation replicates the progression of human glaucoma. - Neurodegenerative phenotypes
Quantifiable RGC apoptosis, axonal transport deficits, and oligodendrocyte injury. - Customizable glaucoma severity
Adjustable ET-1 dosing regimens to model early-stage or advanced glaucoma.
ET-1-Induced Glaucoma Model Evaluation Services
Ace Therapeutics provides comprehensive evaluation services to support the characterization and evaluation of ET-1-induced glaucoma models. Our suite of services is designed to offer in-depth insights into the physiological and pathological changes associated with ET-1-induced glaucoma, ensuring that our clients can assess the efficacy of therapeutic candidates.
- IOP measurement
- Fundus photography and fluorescein angiography
- Vessel diameter and density analysis
- Pattern electroretinography (PERG)
- Retinal flat mount immunostaining
At Ace Therapeutics, our ET-1-induced glaucoma models are not only suitable for investigating IOP-dependent mechanisms, but also capable of exploring the role of IOP-independent mechanisms in the pathogenesis of glaucoma, such as vascular dysregulation. With our customizable animal models and preclinical services, we are committed to helping researchers in elucidating disease mechanisms of glaucoma and supporting drug development initiatives. Contact us to explore how we can support your scientific objectives!
Reference
- Kodati B, et al. The endothelin receptor antagonist macitentan ameliorates endothelin-mediated vasoconstriction and promotes the survival of retinal ganglion cells in rats. Front Ophthalmol (Lausanne), 2023, 3:1185755.